Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PACIFIC-2
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
- NCT03519971 ↗
- Completed
- AstraZeneca
- Deep
We haven't built an HCP commentary report on PACIFIC-2 (durvalumab in unresectable stage III NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PACIFIC-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 126 | |
| Podcasts | 31 | |
| YouTube | 21 | |
| Bluesky threads | 6 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab; Placebo; Cisplatin/ Etoposide; Carboplatin/ Paclitaxel; Pemetrexed/ Cisplatin; Pemetrexed/ Carboplatin; Radiation
- Arms
- Arm 1: Durvalumab + platinum-based chemotherapy and radiation · Experimental
- Arm 2: Placebo + platinum-based chemotherapy and radiation · Placebo comparator
- Enrollment
- 328
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- AstraZeneca
- Start
- Mar 29, 2018
- Primary completion
- Sep 7, 2023
- Results posted
- Yes
- Registry record
- NCT03519971 · updated Jul 14, 2026